WEB NEWS Comments & Business Outlook
“The excellent results for the second quarter and first six months of the year clearly represent how Bristol-Myers Squibb is rapidly transforming into a next-generation BioPharma leader through robust science, superior operational performance and disciplined financial management,” said James M. Cornelius, chairman and chief executive officer. “We are well on-track to continue delivering on our growth commitments. In the second quarter, we extended our collaboration with Otsuka on ABILIFY and, as a result, we expect that our outlook for 2013 is much improved. Our business performance and financial strength position us well to invest in further opportunities for long-term growth .
Bristol-Myers Squibb raised its full 2009 year guidance.
FULL YEAR 2009 Guidance Ending December a
Full Year 2009 Guidance Full Year 2008 Reported Period Change
GAAP EPS
$1.58 to $1.68
$1.59
-1.0% to 5.7%
Non-GAAP EPS b
$1.95 to $2.05
$1.74
12.1% to 17.8%
Source: See Release , July 23, 2009 a The above forecasts reflect the Company's current and preliminary views and are therefore subject to change. Please refer to the Company's Safe Harbor Statement (usually in press releases) for the factors that could cause actual results to differ materially from those contained in any forward-looking statement. b Non-GAAP EPS figures generally exclude certain non-operating gains and losses as well as certain non-cash items. Non-GAAP information should not be viewed in isolation or as a substitute for reported, or GAAP information . For a more complete explanation of the company's definition of non-GAAP please refer to its financial press releases. The GeoTeam ® non-GAAP figures may, from time to time, differ from company supplied figures .
Comments & Business Outlook
“Our operating performance was excellent at both the top and bottom lines,” said James M. Cornelius, chairman and chief executive officer. “We made outstanding strategic progress, taking decisive actions that shift our focus toward future growth as a BioPharma leader. The collaboration agreement we signed with Otsuka gives us improved financial stability in the upcoming years, mitigating some of the volatility we would have otherwise experienced leading up to 2014. We also completed two more transactions that advanced our String of Pearls strategy -- expanding our pipelines in virology and cardiology -- all while maintaining a strong balance sheet and carefully managing costs. Clearly, we are delivering on our commitments to become a stronger, leaner and more effective enterprise.”
The company also reaffirmed guidance for the year.
FULL YEAR 2009 Guidance Ending December a
Full Year 2009 Guidance Full Year 2008 Reported Period Change
GAAP EPS
$1.58 to $1.73
$1.59
-1.0% to 8.8%
Non-GAAP EPS b
$1.85 to $2.00
$1.74
6.3% to 14.9%
Source:
See Release , April 28, 2009
a The above forecasts reflect the Company's current and preliminary views and are therefore subject to change. Please refer to the Company's Safe Harbor Statement (usually in press releases) for the factors that could cause actual results to differ materially from those contained in any forward-looking statement. b Non-GAAP EPS figures generally exclude certain non-operating gains and losses as well as certain non-cash items. Non-GAAP information should not be viewed in isolation or as a substitute for reported, or GAAP information . For a more complete explanation of the company's definition of non-GAAP please refer to its financial press releases. The
GeoTeam ® non-GAAP figures may, from time to time, differ from company supplied figures.
Comments & Business Outlook
Guidance Report : (Non-China)
The company reaffirms guidance that it expects non-GAAP earnings per share from continuing operations to grow at a minimum of 15 percent compounded annual growth rate , from the 2007 base through 2010 without rebasing for the sale of the ConvaTec business, excluding costs associated with the PTI and other specified items that have not yet been identified and quantified.
2009 non-GAAP EPS guidance is $1.85 to $2.00 .
